Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1609
- Registration Number
- NCT03078478
- Locations
- 🇷🇸
Novo Nordisk Investigational Site, Nis, Serbia
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 609
- Registration Number
- NCT02967211
- Locations
- 🇮🇹
Investigational Site Number 380007, Forlì, Italy
🇮🇹Investigational Site Number 380012, Milano, Italy
🇮🇹Investigational Site Number 380026, Padova, Italy
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 705
- Registration Number
- NCT02967224
- Locations
- 🇮🇪
Investigational Site Number 372003, Dublin 4, Ireland
🇮🇪Investigational Site Number 327002, Dublin 7, Ireland
🇫🇷Investigational Site Number 250045, Montpellier, France
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT02964104
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 210
- Registration Number
- NCT02911948
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamaguchi-shi, Yamaguchi, Japan
A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3303
- Registration Number
- NCT02779413
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Wonju, Korea, Republic of
Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 12
- Registration Number
- NCT02680457
- Locations
- 🇲🇽
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 834
- Registration Number
- NCT02670915
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 819
- Registration Number
- NCT02607306
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT02536859
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.